Cargando…
Development of Atomoxetine-Loaded NLC In Situ Gel for Nose-to-Brain Delivery: Optimization, In Vitro, and Preclinical Evaluation
The present study investigates the brain-targeted efficiency of atomoxetine (AXT)-loaded nanostructured lipid carrier (NLC)-laden thermosensitive in situ gel after intranasal administration. AXT-NLC was prepared by the melt emulsification ultrasonication method and optimized using the Box–Behnken de...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386213/ https://www.ncbi.nlm.nih.gov/pubmed/37514171 http://dx.doi.org/10.3390/pharmaceutics15071985 |
_version_ | 1785081606914965504 |
---|---|
author | Mohanty, Dibyalochan Alsaidan, Omar Awad Zafar, Ameeduzzafar Dodle, Trishala Gupta, Jeetendra Kumar Yasir, Mohd Mohanty, Anshuman Khalid, Mohammad |
author_facet | Mohanty, Dibyalochan Alsaidan, Omar Awad Zafar, Ameeduzzafar Dodle, Trishala Gupta, Jeetendra Kumar Yasir, Mohd Mohanty, Anshuman Khalid, Mohammad |
author_sort | Mohanty, Dibyalochan |
collection | PubMed |
description | The present study investigates the brain-targeted efficiency of atomoxetine (AXT)-loaded nanostructured lipid carrier (NLC)-laden thermosensitive in situ gel after intranasal administration. AXT-NLC was prepared by the melt emulsification ultrasonication method and optimized using the Box–Behnken design (BBD). The optimized formulation (AXT-NLC) exhibited particle size PDI, zeta potential, and entrapment efficiency (EE) of 108 nm, 0.271, −42.3 mV, and 84.12%, respectively. The morphology of AXT-NLC was found to be spherical, as confirmed by SEM analysis. DSC results displayed that the AXT was encapsulated within the NLC matrix. Further, optimized NLC (AXT-NLC13) was incorporated into a thermosensitive in situ gel using poloxamer 407 and carbopol gelling agent and evaluated for different parameters. The optimized in situ gel (AXT-NLC13G4) formulation showed excellent viscosity (2532 ± 18 Cps) at 37 °C and formed the gel at 28–34 °C. AXT-NLC13-G4 showed a sustained release of AXT (92.89 ± 3.98% in 12 h) compared to pure AXT (95.47 ± 2.76% in 4 h). The permeation flux through goat nasal mucosa of AXT from pure AXT and AXT-NLC13-G4 was 504.37 µg/cm(2)·h and 232.41 µg/cm(2)·h, respectively. AXT-NLC13-G4 intranasally displayed significantly higher absolute bioavailability of AXT (1.59-fold higher) than intravenous administration. AXT-NLC13-G4 intranasally showed 51.91% higher BTP than pure AXT (28.64%) when administered via the same route (intranasally). AXT-NLC13-G4 showed significantly higher BTE (207.92%) than pure AXT (140.14%) when administered intranasally, confirming that a high amount of the AXT reached the brain. With the disrupted performance induced by L-methionine, the AXT-NLC13-G4 showed significantly (p < 0.05) better activity than pure AXT as well as donepezil (standard). The finding concluded that NLC in situ gel is a novel carrier of AXT for improvement of brain delivery by the intranasal route and requires further investigation for more justification. |
format | Online Article Text |
id | pubmed-10386213 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103862132023-07-30 Development of Atomoxetine-Loaded NLC In Situ Gel for Nose-to-Brain Delivery: Optimization, In Vitro, and Preclinical Evaluation Mohanty, Dibyalochan Alsaidan, Omar Awad Zafar, Ameeduzzafar Dodle, Trishala Gupta, Jeetendra Kumar Yasir, Mohd Mohanty, Anshuman Khalid, Mohammad Pharmaceutics Article The present study investigates the brain-targeted efficiency of atomoxetine (AXT)-loaded nanostructured lipid carrier (NLC)-laden thermosensitive in situ gel after intranasal administration. AXT-NLC was prepared by the melt emulsification ultrasonication method and optimized using the Box–Behnken design (BBD). The optimized formulation (AXT-NLC) exhibited particle size PDI, zeta potential, and entrapment efficiency (EE) of 108 nm, 0.271, −42.3 mV, and 84.12%, respectively. The morphology of AXT-NLC was found to be spherical, as confirmed by SEM analysis. DSC results displayed that the AXT was encapsulated within the NLC matrix. Further, optimized NLC (AXT-NLC13) was incorporated into a thermosensitive in situ gel using poloxamer 407 and carbopol gelling agent and evaluated for different parameters. The optimized in situ gel (AXT-NLC13G4) formulation showed excellent viscosity (2532 ± 18 Cps) at 37 °C and formed the gel at 28–34 °C. AXT-NLC13-G4 showed a sustained release of AXT (92.89 ± 3.98% in 12 h) compared to pure AXT (95.47 ± 2.76% in 4 h). The permeation flux through goat nasal mucosa of AXT from pure AXT and AXT-NLC13-G4 was 504.37 µg/cm(2)·h and 232.41 µg/cm(2)·h, respectively. AXT-NLC13-G4 intranasally displayed significantly higher absolute bioavailability of AXT (1.59-fold higher) than intravenous administration. AXT-NLC13-G4 intranasally showed 51.91% higher BTP than pure AXT (28.64%) when administered via the same route (intranasally). AXT-NLC13-G4 showed significantly higher BTE (207.92%) than pure AXT (140.14%) when administered intranasally, confirming that a high amount of the AXT reached the brain. With the disrupted performance induced by L-methionine, the AXT-NLC13-G4 showed significantly (p < 0.05) better activity than pure AXT as well as donepezil (standard). The finding concluded that NLC in situ gel is a novel carrier of AXT for improvement of brain delivery by the intranasal route and requires further investigation for more justification. MDPI 2023-07-20 /pmc/articles/PMC10386213/ /pubmed/37514171 http://dx.doi.org/10.3390/pharmaceutics15071985 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Mohanty, Dibyalochan Alsaidan, Omar Awad Zafar, Ameeduzzafar Dodle, Trishala Gupta, Jeetendra Kumar Yasir, Mohd Mohanty, Anshuman Khalid, Mohammad Development of Atomoxetine-Loaded NLC In Situ Gel for Nose-to-Brain Delivery: Optimization, In Vitro, and Preclinical Evaluation |
title | Development of Atomoxetine-Loaded NLC In Situ Gel for Nose-to-Brain Delivery: Optimization, In Vitro, and Preclinical Evaluation |
title_full | Development of Atomoxetine-Loaded NLC In Situ Gel for Nose-to-Brain Delivery: Optimization, In Vitro, and Preclinical Evaluation |
title_fullStr | Development of Atomoxetine-Loaded NLC In Situ Gel for Nose-to-Brain Delivery: Optimization, In Vitro, and Preclinical Evaluation |
title_full_unstemmed | Development of Atomoxetine-Loaded NLC In Situ Gel for Nose-to-Brain Delivery: Optimization, In Vitro, and Preclinical Evaluation |
title_short | Development of Atomoxetine-Loaded NLC In Situ Gel for Nose-to-Brain Delivery: Optimization, In Vitro, and Preclinical Evaluation |
title_sort | development of atomoxetine-loaded nlc in situ gel for nose-to-brain delivery: optimization, in vitro, and preclinical evaluation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386213/ https://www.ncbi.nlm.nih.gov/pubmed/37514171 http://dx.doi.org/10.3390/pharmaceutics15071985 |
work_keys_str_mv | AT mohantydibyalochan developmentofatomoxetineloadednlcinsitugelfornosetobraindeliveryoptimizationinvitroandpreclinicalevaluation AT alsaidanomarawad developmentofatomoxetineloadednlcinsitugelfornosetobraindeliveryoptimizationinvitroandpreclinicalevaluation AT zafarameeduzzafar developmentofatomoxetineloadednlcinsitugelfornosetobraindeliveryoptimizationinvitroandpreclinicalevaluation AT dodletrishala developmentofatomoxetineloadednlcinsitugelfornosetobraindeliveryoptimizationinvitroandpreclinicalevaluation AT guptajeetendrakumar developmentofatomoxetineloadednlcinsitugelfornosetobraindeliveryoptimizationinvitroandpreclinicalevaluation AT yasirmohd developmentofatomoxetineloadednlcinsitugelfornosetobraindeliveryoptimizationinvitroandpreclinicalevaluation AT mohantyanshuman developmentofatomoxetineloadednlcinsitugelfornosetobraindeliveryoptimizationinvitroandpreclinicalevaluation AT khalidmohammad developmentofatomoxetineloadednlcinsitugelfornosetobraindeliveryoptimizationinvitroandpreclinicalevaluation |